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[57] ABSTRACT 
2.4-disulfonyl ot-phenyl-tert-butyl nitrone and its pharma— 
ceutically acceptable salts are disclosed. These materials are 
useful as pharmaceutical agents for oral or parenteral. e.g. 
intravenous administration to patients su?’ering from acute 
central nervous system oxidation as occurs in a stroke or 
from gradual central nervous system oxidation which can 
exhibit itself as progressive central nervous system function 
loss. The materials are also used to ameliorate the side 
elfects of oxidative-damage causing antineoplastic disease 
treatments. 
40 Claims, 6 Drawing Sheets 

US. Patent 
TEMP. (c) 
TEMP. (C) 
TEMP. (c) 
40.0 
38.0 
36.0 
34.0 
32.0 
38.0 
37.0 
36.0 
35.0 
34.0 
33.0 
32.0 
38.0 
37.0 
36.0 
35.0 
34.0 
33.0 
32.0 
Jul. 14, 1998 Sheet 2 0f 6 
MOUSE Saline 
~OO/O_O—O——O\O_______‘O“_O 
I I I I I I I I 
0 3O 60 90 120150180 210 240 
TIME (min) 
MOUSE 100 mg/kg PBN 
-o 
- (RR, I I I I I I I I 
0 30 60 90 120150 I80 210 240 
TIME (min) 
MOUSE IOOmq/kg Compound I 
Oyo-0’°\o'-O—°_0 
I I I I I I I I 
0 30 50 90 120150180 210 240 
TIME (min) 
5,780,510 
2A 
2B 
2C 
US. Patent Jul. 14, 1998 Sheet 3 of 6 5,780,510 
E5 m2: 
39326838 8on0GT0? ~h_hp_____o.mw 275828 I 08 I. 35:88 1 0.2 m
.d 
1 0% w
1; I. C 3% > 5%:32Gm .U?m
EEV m1: 
22585938 8on078.. ww______p_o.mm 
| Q8. 
1 
| 0.2 m
.d 
1 in w
zma $8208 (
I 0.3 
C 3% 
> 5%:22mm. .Uwm
E5 M2: 
o¢wowmom?onpo?om n0nio : _.___P_____o.mN | Q3 223228 1 93308 | in m
.d 
1 3n @
I odn 
I; V 2% or 5mm :2:0m (UFHE3 M2: 22223598 8onQ.9T ________P_o.wm | 0.3 
M 
23 | 0.3 M
1 in w
| 0.3 
olllzlolildllnvloroé C 0.2 > 550:2:4m .Urm

US. Patent Jul. 14, 1998 Sheet 5 0f 6 5,780,510 
m .UE
hmca m zorn50m$523on
H ozaomzoo
o m + m m op 
52: 5%M239 6%;

5.780.5l0 
l 
ZA-DISULFO PHENYL BUTYL NITRONE, 
ITS SALTS AND THEIR USE AS 
PHARMACEUTICALS 
CONTINUING DATA 
This application is a continuation-in-part (CIP) of Ser. No. 
08/173579. ?led on Dec. 23. 1993. now US. Pat. No. 
5.488.145. 
BACKGROUND OF THE INVENTION 
This invention relates to a particular nitrone compound 
and its salts and their advantageous use as pharmaceutical 
nitrone free radical trapping agents. 
Alpha-phenyl tert butyl nitrone 
or “PBN”) was identi?ed in the 1970s as a useful analytical 
reagent to be used in conjunction with electron spin reso 
nance (“ESR") to aid in the detection of free radicals. PBN 
was found to react with certain free radicals and generate a 
chemical species yielding a characteristic ESR spectrum and 
thus making it possible to determine the presence or absence 
of free radicals. 
In the late 1970s and early 1980s the medical community 
began to focus on the roles played by free radicals in 
diseases such as heart attacks. strokes and the like. PBN was 
used increasingly in vitro to provide analytical evidence of 
the presence of free radicals in these settings. It was also 
later administered in vivo in animal models. again as an 
analytical adjunct in attempts to observe free radicals during 
ischemia simulations and the like. 
In the mid 1980s. the ?rst possible therapeutic effects of 
PBN were implied when severe trauma ischemia animal 
tests showed that PEN-treated animals were more likely to 
survive than controls. 
On May 2. 1991. PCI‘ patent application WO-91-05552 
was published. This patent application. which in part cor 
responds to now-issued US. Pat. Nos. 5.825.032 and 5.036. 
097. described PBN and a family of PBN derivatives de?ned 
by the formula 
H O’ 
C=N+ 
X Y 
wherein 
X is phenyl or 
(0R), 
where R is H. 
0 
ll 
Z-C -—, 
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and n is a whole integer from 1 to 5 or 
and Y is tert-butyl or a hydroxylated or acetylated tert-butyl 
or a substituted phenyl. These compounds were proposed as 
pharmaceutical agents to treat the aftermath of stroke and 
other conditions reported to be associated with free radical 
damage. 
In 1992 a second PCT patent application was ?led 
directed to PBN and related compounds and their medical 
use. This application. based on prior US. patent application 
Ser. No. 716.952 (?led Jun. 18. 1991). was published on 
Dec. 23. 1992 as WO 92/22290. This 1992 publication 
provided two extremely broad and general disclosures. First. 
it attempted to describe as many disease states as possible 
which were associated with free radicals. These ranged from 
CNS conditions (including stroke. aging. migraine. etc.) 
through peripheral organ disease (including atherosclerosis. 
bed sores. wounds. and muscle overexertion) through UV 
exposure. to mention but a few highlights. Second. it 
attempted to list as many potential spin traps as possible. 
In addition to a Whole range of non-PBN materials. this 
application greatly expanded the de?nition of potentially 
useful PBN compounds to include PBN. and derivatives 
thereof of the formula 
wherein 
X is phenyl. imidazolyl. phenothiazinyl or 
(R2). 
n=1—5. preferably 1-3; 
R2=independently (can vary within the molecule) 
halogen. alkyl. oxyalkyl. alkenyl. oxyalkenyl. OH. 
NH2. NHZ. NZ2. NO. 
—SO_.H. -—OSO3H. SH. —S(alkyl). —S(Valkenyl. and 
haloalkyl. speci?cally including —CF3: 
5.780.5l0 
3 
A=O or S: and 
Z is a C1 to C6 straight. branched. alkyl or cyclic group: 
and 
Y is a tert-butyl group that can be hydroxylated or 
acetylated at one or more positions: phenyl or 
(R2), 
PBN was stated to be the most preferred compound at that 
time. being said to have no measurable effect on normal or 
uninjured cells. and a number of derivatives were also stated 
to be useful. including hydroxy derivatives. especially 2-. 3 
or 4-hydroxyphenyl t-butyl nitrone and phenyl (mono-. di 
or trihydroxy) tert-butyl nitrone: PBN esters. especially 
esters which release 2-. 3-. or 4-hydroxyphenyl t-butyl 
nitrone such as acetoxy derivative; 2-. 3-. or 
4-carboxyphenyl t-butyl nitrone; phenyl hydroxybutyl 
nitrone; alkoxyl derivatives. especially alkoxyl derivatives 
which release 2-. 3-. or 4-hydroxyphenyl t-butyl nitrone. for 
example. the 2-. 3-. or 4-methoxyphenyl derivatives of PBN: 
and acetamide derivatives. especially acetamide derivatives 
which release 2-. 3-. or 4-arninophenyl t-butyl nitrone; 
diphenyl nitrone (PPN) and the analogous diphenyl nitrone 
derivatives; N-tert-butyl-ot-(4-nitro-phenyl) nitrone; and 
N-tert-butyl-ot-(2-sulfophenyl) nitrone. 
STATEMENT OF THE INVENTION 
It has now been discovered that one particular PBN 
derivative and its salts have unexpectedly superior pharma 
cological properties. Although this derivative. 2.4-disulfo 
PBN. falls Within the broad family of materials generally 
described in the aforementioned W0 92/022290 publication. 
it is not speci?cally disclosed Neither are its advantageous 
properties predicted. 
The present compound with its two sulfonate groups was 
expected to exhibit improved water solubility but was also 
expected to exhibit poor transport across the blood/brain 
barrier because of its lipophobic character. However. when 
the present compound was made and tested in vivo. it 
showed an unexpected increase in e?icacy as compared to 
PBN. This increase in e?icacy occurred along with an 
increase in potency as compared to PBN. In direct contrast 
to this marked increase in potency and e?icacy there was a 
marked and highly signi?cant decrease in toxicity as com 
pared to PBN. 
These results were unexpected because in the general 
literature on structure/activity relationships within speci?c 
de?ned families of compounds therapeutic potency typically 
covaries with toxicity. Thus. most related compounds main 
tain their ratio of therapeutic potency to toxicity. In contrast. 
the compound of this invention deviates from this expected 
relationship when its potency increased and its toxicity 
decreased relative to closely related analogs. 
Accordingly. in one aspect. the invention provides the 
PBN-disulfonyl compound 
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and its pharmaceutically acceptable salts. 
In a second aspect. the invention provides parenterally-. 
e.g. intravenou sly- and orally-adrninistrable pharmaceuticzd 
compositions having this compound or its salt as active 
ingredient. 
In a third aspect. this invention provides a method for 
treating a patient who is su?’ering from a condition involving 
acute oxidative damage to the central nervous system. such 
as a patient who has suffered a stroke. in which a pharma 
ceutical composition based on this compound or its salt is 
administered parenterally. e.g. intravenously. 
In a fourth aspect. this invention provides a method for 
treating a patient suffering from a condition characterized by 
protracted low grade oxidative stress upon the central ner 
vous system and progressive loss of central nervous system 
function. In this method. a pharmaceutical composition 
based on this compound or its salt is administered 
parenterally. e.g. intravenously or preferably orally. 
In a ?fth aspect. this invention provides a method for 
reducing or ameliorating the side-effects arising from oxi 
dative damage produced in a patient by cancer therapy. In 
this method a pharmaceutical composition based on this 
compound or its salt is administered parenterally. e.g. intra 
venously or orally. 
DETAILED DESCRIPTION OF THE 
INVENTION 
This Detailed Description is arranged into the following 
sections: 
Brief Description of Drawings. 
The Compounds and Salts. 
Compound Preparation. 
Pharmaceutical Compositions. 
Conditions Treated and Treatment Regimens. 
Examples. 
BRIEF DESCRIPTION OF THE DRAWINGS 
In this speci?cation reference will be made to the accom 
panying drawings in which 
FIG. 1 is a schematic ?ow chart of the reactions used to 
prepare the compound. 
FIGS. 2 (A. B and C) and 3 (A. B. C. and D) are two sets 
of graphs illustrating the undesirable change in animal body 
thermal regulatory ability which occurs as a function of dose 
level with a prior art nitrone radical trapping agent and 
contrasting this with the lack of such undesired toxic effect 
with the compound of the invention. 
FIG. 4 (A. B. C. and D) is a set of four graphs demon 
strating the superiority of the compound of the invention as 
compared to a closely related prior art nitrone compound in 
the treatment of gradual neurodegeneration conditions (such 
as Alzheimer’s disease) as illustrated by their relative ability 
to interfere with beta amyloid protein‘s inactivation of key 
enzymes in solution. 
FIG. 5 is a graph illustrating the effectiveness of the 
compound of the invention in reducing the ultimate infarct 
volume observed following middle cerebral artery occlusion 
in rats. 
5.780.510 
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FIGS. 6 (A. B and C) are three graphs illustrating the 
ability of the compound of the invention to reduce the 
side-effects in animals of high dose levels of anticancer 
agents. 
THE COMPOUND AND SALTS 
The compound of this invention is 2.4—disulfonyl 
ot-phenyl tertiary butyl nitrone. It is also referred to infor 
mally herein as “2.4-disulfon PBN” or “PBN 2.4 
disulfonate." It exists in an acid form 
as a solid and in solution in low pH conditions. It also exists 
at higher pHs in an ionized salt form which can be shown as 
where X is a pharmaceutically acceptable cation. Most 
commonly. this cation is a monovalent material such as 
sodium. potassium or ammonium. but it can also be a 
multivalent cation alone or in combination with a pharma 
ceutically acceptable monovalent anion. for example cal 
cium with a chloride. bromide. iodide. hydroxyl. nitrate. 
sulfonate. acetate. tartrate. oxalate. succinate. palmoate or 
the like anion; magnesium with such anions; zinc with such 
anions or the like. When these combinations of a polyvalent 
cation and a monovalent anion are illustrated in structural 
formulae. herein. the monovalent anion is identi?ed as “Y”. 
Among these materials. the free acid and the simple 
sodium. potassium or ammonium salts are most preferred 
with the calcium and magnesium salts also being preferred 
but somewhat less so. 
COMPOUND PREPARATION 
As detailed in FIG. 1 and demonstrated in Example 1. the 
compound of this invention can be prepared by a two step 
reaction sequence. In the ?rst step. commercially available 
tertiary butyl nitrate (Z-methyLZ-nitropropane) is converted 
to the corresponding n-hydroxyl amine using a suitable 
catalyst such as an activated zinc/acetic acid catalyst or an 
aluminum/mercury amalgam catalyst. This reaction can be 
carried out in 0.5 to 12 hours and especially about 2 to 6 
hours or so at a temperature of about 15° to 100° C. in a 
liquid reaction medium such as alcohol/water mixture in the 
case of the zinc catalyst or an ether/water mixture in the case 
of the aluminum amalgam catalyst. 
In the second step. the freshly formed hydroxylamine is 
reacted with 4-formyl-1.3-benzenedisulfonic acid. typically 
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with a slight excess of the amine being used. This reaction 
can be carried out at similar temperature conditions. This 
reaction is generally complete in 10 to 24 hours. 
The product so formed is the free acid and is characterized 
by a molecular weight of 89 g/mole. It is a white powdery 
material which decomposes upon heating. It is characterized 
by a solubility in water of greater than 1 gram/ml and a 1H 
NMR spectrum in D20 of 8.048 ppm (dd. 8.4. 1.7 Hz): 8.836 
ppm (d. 8.4 Hz); 8.839 ppm (d. 1.7 Hz): 8.774 ppm (s). 
The various salts can be easily formed by admixing the 
free acid in aqueous medium with two equivalents of the 
appropriate base. for example. KOH for the potassium salt. 
and the like. 
PHARMACEUTICAL COMPOSITIONS 
The compound (including its salts) can be formulated into 
pharmaceutical compositions suitable for oral or parenteral. 
e.g. intravenous or intramuscular injection administration. 
The compositions for oral administration can take the 
form of liquid solutions or suspensions. powders. tablets. 
capsules or the like. In such compositions. the PBN 2.4 
disulfonate or its salt is usually a minor component (0.1 to 
say 50% by weight) with the remainder being various 
vehicles or carriers and processing aids helpful for forming 
the desired dosing form. A liquid form may include a 
suitable aqueous or nonaqueous vehicle with buffers. sus 
pending dispensing agents. colorants. ?avors and the like. 
A solid form may include. for example. any of the 
following ingredients. or compounds of a similar nature: a 
binder such as microcrystalline cellulose. gum tragacanth or 
gelatin; an excipient such as starch or lactose. a disintegrat 
ing agent such as alginic acid. Primogel. or corn starch; a 
lubricant such as magnesium stearate; a glidant such as 
colloidal silicon dioxide; a sweetening agent such as sucrose 
or saccharin; or a ?avoring agent such as peppermint. sugar. 
methyl salicylate. or orange ?avoring. 
In the case of injectable compositions. they are commonly 
based upon injectable sterile saline or phosphate-buffered 
saline or other injectable carriers known in the art. Again the 
active nitrone is typically a minor component. often being 
from about 0.05 to 10% by weight with the remainder being 
the injectable carrier and the like. 
Conditions Treated and Treatment Regimens 
The conditions treated with the 2.4.disolfo PBN generally 
fall into three groups. The ?rst includes conditions involving 
acute intense oxidative damage to a region of the central 
nervous system. Examples of these conditions include 
stroke. conditions associated with stroke. concussion and 
subarachnoid hemorrhage. In this setting. the compound is 
administered in a manner designed to get the drug into the 
patient’s bloodstream as quickly and directly as possible. 
This usually means intravenous administration. 
Intravenous dose levels for treating these conditions range 
from about 0.1 mg/kg/hour to at least 10 mg/kg/hour. all for 
from about 1 to about 120 hours and especially 24 to 96 
hours. A preloading bolus of from about 10 to about 500 mg 
may also be administered to achieve adequate steady state 
levels. 
While intravenous administration is preferred. other 
forms of parenteral administration. such as intramuscular 
injection can be used. as well. In this case. similar dose 
levels are employed. An unexpected and key advantage of 
2.4.disulfo PBN is that it can be administered at vastly 
higher levels than are possible with PBN itself. As will be 
5.7805 l0 
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shown in the Examples. doses of up to 1000 mg/kg/hour and 
higher or intravenous bolus doses of from 10 to 2500 mg/kg 
have been demonstrated to be possible with 2.4.disulfo PBN 
or its salts while with PBN itself death or acute toxicity 
results from such doses. _With 2.4.disulfo PBN there is an 
unexpected positive continuance of the dose/response curve 
in these high dose levels with the clear message that intense 
heavy dosing immediately post stroke or other trauma may 
in many cases provide a major positive impact upon recov 
cry. 
The second group of conditions which respond favorably 
to 2.4.disulfo PBN treatment are conditions characterized by 
protracted low grade oxidative stress upon the central ner 
vous system and gradual progressive central nervous system 
function loss. These conditions include Alzheimer's disease. 
Parkinson’s disease. arnyotrophic lateral sclerosis (ALS). 
multi-infarct dementia. retinopathy and the like. Each of 
these conditions is characterized by a progressive loss of 
function. 2.4-disulfonyl-PBN or its salts. when administered 
orally or parenterally. e.g. intravenously. can slow and 
possibly reverse the loss of function. If parenteral. e.g. 
intravenous administration is desired. similar levels to those 
used with acute conditions but at the lower end of the ranges 
are generally used. 
In these cases. the regimen for treatment may stretch over 
many months or years so oral dosing is preferred for patient 
convenience and tolerance. With oral dosing. one to three 
oral doses per day. each from about 0.02 to about 50 mg/kg 
are called for with preferred doses being from about 0.04 to 
about 5.0 mg/kg. 
Of course. one can administer 2.4-disu1fonyl PBN as the 
sole active agent or one can administer it in combination 
with other agents. This leads to a third application for this 
compound. 
A third set of conditions which respond to treatment with 
2.4.disulfo PBN are the side-etfects which arise in patients 
from oxidative damage produced by cancer (neoplastic 
disease) therapy. The therapy which produces the oxidative 
damage (and thus the side effects) includes radiation (e.g. 
gamma radiation) therapy and therapy with oxidative 
damage causing chemotherapeutic agents. Examples of 
these agents include antibiotics such as daunorubicin. doxo 
rubicin and bleomycin; procarbazine; nitrogen mustards 
such as ifosfarnide. melphalan and chlorambucil; alkylating 
agents; antimetabolites; hormones and antagonists. 
Administration of 2.4.disulfo PBN can have the effect of 
reducing patient discomfort during these therapies. In 
addition. administration of the compound of this invention 
can increasing patients‘ ability to tolerate these therapies. 
Often the side effects of therapies force the discontinuance 
of these therapies or prevent the administration of optimal 
high doses or rapid frequencies of these therapies. In some 
cases these side effects are devastatingly destructive and 
lead to heart failure and other major function loss. In tests in 
animals it has been observed that the compound of the 
invention can improve patient tolerance of these antine 
oplastic disease treatments. 
In this therapy. the compound of the invention may be 
administered before. during and after the radiation or che— 
motherapy is administered. Administration may be 
parenteral or oral or by any other method which will permit 
the 2.4-disulfonate PBN to enter the patient’s bloodstream. 
A positive dose-response relationship has been observed 
As such. and bearing in mind the severity of the side effects 
and the advantages of providing maximum possible protec 
tion or amelioration. it may be desired in some settings to 
20 
25 
30 
35 
45 
50 
55 
65 
8 
administer large amounts of 2.4.disulfo PBN such as those 
described above for the acute intense oxidative CNS damage 
conditions. In other settings lower doses. such as those set 
forth for the progressive neuronal disease therapy. may be 
used. 
The following are examples of representative administra 
tion regimens: In monotherapy (adriamycin alone) two 
representative dose combinations are 10-600 mg Compound 
I per square meter area plus 60 mg adriamycin per square 
meter of surface area with adriamycin dosing occurring 
every seven or twenty-one days. Compound I may be 
administered before the adriamycin. for example. up to 60 
minutes before. at the same time or after. such as hours after 
and on subsequent days. The pediatric dose is typically 
lower for both drugs. Higher doses may be used for treat 
ment of multidose resistant tumors. 
EXAMPLES 
Example 1 
Synthesis of 2.4-disulfophenyl-N-t-butylnitrone 
(Compound “I” in subsequent Examples). This preferred 
synthesis is based on the work by R. H. Hinton and E. G. 
Janzen (J. Org. Chem. 57:2646-2651. 1992). As shown in 
FIG. 1 it involves the condensation of an aldehyde with a 
hydroxylamine. The hydroxylamine is unstable and is pre 
pared fresh on the day of use using an activated zinc catalyst. 
The synthesis is as follows: 
Prerequisite Chemicals 
. 95% Ethanol 
. 2-Methyl-2-nitropropane 
. Zinc dust 
4. Glacial acetic acid 
5. Diethyl ether 
6. Saturated sodium chloride 
7. Magnesium Sulfate. Anhydrous solid 
8. 4-Formyl-1.3-benzenesulfonic acid (MW 310.21 
g/mole). disodium salt. hydrate 
9. Methanol 
l0. Dichloromethane 
LAN’ 
Procedure 
A. Preparation of N-t-Butylhydroxylamine 
1. A 500 ml three neck round bottom ?ask is equipped 
with a magnetic stir bar. thermometer adapter. 
thermometer. and addition funnel. 
2. 95% ethanol (350 ml) was added to the ?ask and cooled 
to 10° C. in an ice bath. 
3. 2-Methyl-2-nitropropane (6.18 g. 0.060 mole). and zinc 
dust (5.89 g. 0.090 mole) were added in single portions. 
4. Glacial acetic acid (10.8 g. 0.180 mole) was placed in 
the addition funnel and added dropwise at such a rate 
with vigorous stirring to maintain the temperature 
below 15° C. 
5. The ice bath was removed and mixture was stirred for 
3 hrs at room temperature. 
6. The solvent was stripped from the mixture. leaving 
t-butylhydroxylarnine. zinc acetate. and water. 
7. Dichloromethane (50 ml) was added and the mixture 
?ltered through a Buchner funnel. 
8. The zinc acetate cake left on the ?lter paper was washed 
with 2x25 ml dichloromethane. 
5.780.510 
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9. Water was separated from the ?ltrate in a separatory 
funnel and the organic layer dried over magnesium 
sulfate. 
10. The magnesium sulfate was removed by ?ltering 
through ?uted ?lter paper. then dichloromethane 
stripped o? by rotary evaporation. 
11. The product (100% yield=5.34 g). a viscous liquid. 
was dissolved in methanol (50 ml) for use in part B. 
B. Preparation of 2.4-disulfonylphenyl-N-t-butylnitrone 
1. A 3-neck 250 ml round bottom ?ask was set up with a 
stir bar. a gas dispersion tube. an addition funnel. and 
a Friedrichs condenser cooled with recirculating ice 
water. 
2. To the ?ask were added 200 ml of methanol. 4-formyl 
1.3-benzenedisulfonic acid (9.31 g. 30 mmoles) and 
N-t-butylhydroxylamine (25 ml of the methanol solu 
tion from part A. 30 mmoles theoretical). 
3. The reaction was heated to re?ux with a heating mantle 
while bubbling the reaction with nitrogen with stirring. 
4. The mixture was re?uxed for 2 hours. 
5. The remainder of hydroxylamine from part A was 
added. 
6. Re?uxing was continued with nitrogen bubbling for at 
least 18 hours. but not more than 24 hours. 
7. The hot reaction mixture was ?ltered on a Buchner 
funnel. and the solid washed with hot methanol. 
8. The methanol was stripped off by rotary evaporation to 
a yellow. viscous oil. 
9. Hot 1:1 ethanolzacetone (200 ml) was added and the 
mixture heated to dissolve the oil. 
10. The solution was cooled to crystallize the product. 
11. The product was collected on a Buchner funnel and 
dried under vacuum overnight. 
12. The reaction typically gives 75% yield of Compound 
I. a white powder. 
Example 2 
Alternate Synthesis of 2.4-disulfonylphenyl-N-t 
butylnitrone (Compound I). This is an earlier-developed 
method which used to prepare samples of the compound 
used in several of the experiments reported in the Examples 
of this speci?cation. The product of this Example is identical 
in all ways to the product of Example 1. This synthesis 
method is as follows: 
Prerequisite Chemicals 
1. Aluminum Foil. cut into 5 cm wide strips and rolled in 
a ca. 1 cm diameter cylinder 
2. Mercury (II) Chloride (9.68 g in 476 ml water) 
3. Ethanol 
4. Ether (6 l) 
5. Pure Water 
6. 2-Methyl-2-nitropropane 
7. Sodium Hydroxide. 2M (80 g in 11 water) 
8. Magnesium Sulfate. Anhydrous solid 
9. 4-Formyl-1.3-benzenesulfonic acid (MW 310.21 
g/mole) 
Procedure 
A. Preparation of N-t-Butylhydroxylamine 
1. Aluminum foil cylinders were dipped into HgCl2 
solution for 15-30 seconds. then dipped in ethanol. 
then dipped in ether and then placed into a 5 l ?ask 
containing 500 ml of diethyl ether and 21.4 ml of water. 
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2. The ?ask was ?tted with a 250 ml pressure-equalizing 
dropping funnel. a mechanical stirrer. a nitrogen inlet. 
and a Friedrichs condenser cooled with recirculated ice 
water. 
3. The mixture was stirred for 10 minutes. 
4. 2~Methyl-2-nitropropane (71.68 g. 75.5 ml) was added 
using the dropping funnel at such a rate as to maintain 
a vigorous re?ux. 
NOTE: Addition must be completed in less than 20 
minutes or the yield drops signi?cantly. 
5. As the addition proceeded. ether was added in 500 ml 
portions. This was done to maintain as high a concen— 
tration of product as possible without the formation of 
a gel. Up to 2 l of ether can be added with no deleterious 
e?ects on the yield. 
6. Once addition of 2-methyl-2-nitropropane was 
complete. the reaction was stirred for an additional 30 
minutes. 
7. The resulting gray suspension was suction ?ltered in 3 
batches to remove aluminum salts. 
8. Each ?lter cake was washed with l l of ether. 
9. The combined either layers were washed with 300 ml 
of 2M NaOH. then dried (M gSO4). and concentrated in 
vacuo to leave a soft white solid. 
10. The solid melts just above room temperature. but 
could be dried further in a vacuum oven (no more than 
a few minutes). leaving 38 to 45 g of solid. 
11. The solid can be used as is or was puri?ed by 
recrystallization from pentane. 
12. Molecular weight—89 g/mole. 
B. Preparation of 2.4-disulfonylphenyl-N-t-butylnitrone 
1. A 250 ml ?ask was equipped with a stir bar and a 
Friedrichs condenser cooled with recirculated ice 
water. 
2. The ?ask was charged with 71.8 ml of methanol. 14.5 
g of 4-formyl-1.3-benzenedisulfonic acid (46.7 
mmoles. 1 eq.). and 5.0 g of N-t-butylhydroxylamine 
(56.2 mmoles. 1.2 eq.). 
b) . The mixture was re?uxed overnight. 
4. The reaction product was transferred to round-bottom 
?ask and rotovaped to dry. 
5. The solid residue was mashed with ether. the ether was 
decanted off (yellow). 
6. Step 5 was repeated. 
7. Product (“Compound I”) was crystallized from metha 
nol following a hot methanol ?ltration to remove 
insoluble precipitates and recrystallized twice from 
methanol. 
Example 3 
A series of experiments were carried out to compare in 
vivo the e?icacy of 2.4 disulfo PBN (“Compound I"). PBN. 
and two monosulfonate PBN compounds as agents for 
protecting against neuron loss following brain ischemia and 
reperfusion injury. The test procedure is that reported by W. 
Cao. J. M. Carney. A. Duchon. R. A. Floyd and M. Chevion 
as “Oxygen free radical involvement in ischemia and rep 
erfusion injtu'y to brain. Neuroscience Letters, 88 (1988). 
233. In the experiments a test compound was administered 
to groups of six gerbils i.p. as a single dose 30 min before 
5 min bilateral carotid occlusion. The density of neuronal 
nuclei in a 100 micron was measured. Two controls were 
present—controls which received no test compound and 
controls which received no test compound and no brain 
5.780.510 
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ischemia. As illustrated in Table l. the compound of the 
invention showed unexpected advantages as compared to the 
prior an compounds. First. it is seen that at low dose levels. 
such as 3.2 mg/kg. compound I is 2-3 times as potent at 
preventing neuronal loss. At high dose levels it is seen that 
Compound I is able to achieve complete protection against 
neuronal loss as the test brains showed neuronal densities 
identical to the non-ischemic controls. The prior art com 
pounds are either toxic at these dose levels or showed 
signi?cantly lower degrees of protection. These results show 
a clear increase in potency for neural protection for com 
pound I compared to PBN and two closely related analogs 
and an unexpected decrease in toxicity compared to PBN. 
TABLE 1 
Neuronal nuclei/100 micron ?eld 
2- 3- Cmpd. 
PBN sul sulfo I 
Non-ischemic control 4.21 4.21 4.21 4.21 
(.43) (.43) (.43) (.43) 
Ischemic control 0.58 0.58 0.58 0.58 
(.28) (.28) (.28) (.28) 
3.2 mgfkg 0.43 0.73 0.35 1.43 
(.18) (.34) (.21) (.31) 
1O rug/kg 1.13 0.68 0.81 2.57 
(.39) (.31) (.40) (.25) 
32 mg/kg 1.83 0.73 1.63 3.53 
(.21) (.31) (.35) (.41) 
SOmg/kg 3.11 1.01 1.63 4.11 
(.29) (.61) (.35) (.43) 
100 mg/kg 3.68 0.93 1.93 4.18 
(.71) (.53) (.39) (.49) 
320 mg/kg 3.78 1.11 1.78 4.23 
(.43) (.41) (.40) (.39) 
1000 mg/lrg Toxic 0.98 1.58 4.11 
(.43) (.38) (.41) 
3200 mg/kg Toxic —— — 4.18 
Example 4 
A series of experiments were conducted in which com 
pound Iwas compared to PBN and two sulfonate analogs in 
post-ischemia treatment. The general method described in 
example 1 was used but the test compounds were adminis 
tered i.p. as a single dose 30 min after reperfusion following 
5 min ischemia. The results are summarized in Table 2. 
Table 2 shows that the compound of the invention is again 
more potent at low doses and more potent and less toxic at 
high doses. Also again. toxicity interferes with the ability of 
the prior art compounds to go to high doses at which levels 
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TABLE 2-continued 
Neuronal nuclei/100 micron field 
2- 3- Cmpd. 
PBN srlfo sulfo I 
320 rug/kg 2.25 0.81 0.93 3.55 
(.43) (.31) (.48) 
1000 lug/kg Toxic ND ND 3.68 
(.39) 
Example 5 
Compound I is compared with PBN to determine the 
relative e?ectiveness for protection of neuronal loss when 
administered i.v. 60 min after reperfusion onset following 5 
min ischemia in gerbils using the general test method 
described in Example 1.. The results are summarized in 
Table 3. and illustrate that compound I is of signi?cantly 
greater therapeutic bene?t in a clinical treatment setting 
following injury to the brain. 
TABLE 3 
N = 6 per group mg/kg single dose 
0.0 0.5 1.0 10 
Saline. no ischemia 4.11 — — — 
(.23) 
saline, ischemia 0.93 — — — 
(J7) 
PBN — 0.83 1.07 1.23 
(.23) (.29) (.31) 
Compound I — 1.25 1.75 2.43 
(.19) (.28) (.31) 
Neither PBN nor Compound I. had an e?ect on neuronal 
density in control gerbils without brain injury. 
Example 6 
Brain injury can manifest itself as behavioral changes. In 
this experiment. young adult (3-4 months of age) gerbils 
were tested to determine their ability to perform an S-arm 
maze test 24 hours following an ischemic event as described 
in Example 1. As compared to nonischemic animals. when 
untreated they committed many more errors. PBN and 
compound I were administered to some of the test animals. 
As detailed in Table 4. gerbils treated with high doses of 
compound I had error levels indistinguishable from those of 
nonischemie animals. PBN was less etfective. This shows 
. . . . _ 50 ' the compound of the 1nvent1on provides dramatically effec that compound I can protect against thg loss of temporal] 
ave therapy‘ spatial short term memory following ischemia (24 hours 
post) errors in 8-arm radial maze test of young gerbils 
TABLE 2 following 5 min ischemia. 
Neuronal nuclei/100 micron ?eld 55 
TABLE 4 
2. 3- Cmpcl. 
PBN sul sulfo I N = 6 per group mg/kg/hr for 24 hours 
Non-ischemic control 4.18 4.18 4.18 4.18 0.0 1.0 32 50 100 
(.59) (.59) (.59) (.59) 60 Control 4.1 _ - _ 
Ischemic control 0.85 0.85 0.85 0.85 (.38) 
(.19) (.19) (.19) (.19) Postischemic 37.6 — ~ _ 
32 mg/kg 109 ND ND 1.83 (4.85) 
(.31) (.41) PBN _ 29.8 18.19 6.23 5.83 
SOmg/kg 1.85 0.68 0.73 2.73 (7.27) (5.83) (.71) (.49) 
(.49) (.31) (.34) (.39) CompoundI _ 14.63 7.19 4.28 4.11 
100 mg/kg 2.11 0.78 1.09 3.41 65 (3.81) (.81) (.29) (.19) 
(.51) (.23) (.48) (.37) 
5.780.510 
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Example 7 
The ability of the compound of the invention to reduce 
infarct volume following an ischemic event was determined. 
As detailed in Table 5. it was observed that while PBN and 
compound I were both eifective at low doses. at high doses 
I gave the best protection and PBN was toxic. Table 5 shows 
the infarct volume observed when test compound was 
administered iv. 60 min after middle cerebral occlusion and 
continued for 24 hours in C57BL/6] mice. 
TABLE 5 
Infarct Volume in mm3 
Posttreatment 0.0 1.0 10 100 
Control, no ischemia 0 — - — 
Saline, ischemia 23 — — — 
(2) 
PEN — 17.7 13.8 Toxic 
(2.8‘) (2.3) 
Compound I -— 16.8 12.7 8.3 
(1.7) (3.93) (.71) 
Example 8 
In this study. compound I and PBN are compared for their 
ability to impart lethality protection (% survived) in aged 
gerbils (18-24 months of age. n=l2/group) from 10 rnin 
ischemia when given 30 min before ischemia. As shown in 
Table 6. compound I is superior at all dose levels and 
achieved complete protection at high levels while PBN is 
only partially e?‘ective. 
TABLE 6 
Pretreatment 0.0 10 32 MI) 320 
(mg/kg) 
Saline — — — — 
PBN — 42 50 75 92 
Compound I — 50 75 100 100 
Example 9 
An important advantage of the compound of this inven 
tion as compared to the art-taught compound. PBN. is its 
markedly diminished toxicity. As detailed in Table 7. acute 
lethality in C57BL/6L mice was determined based upon 
varying sizes of single i.p. doses of nitrone. PBN showed 
signi?cant toxicity at 560 mg/kg dose levels. Compound I 
showed no toxicity at doses nearly twenty times as great. 
TABLE 7 
Ins/ks 
% Survival 320 560 1000 3000 10000 
n = Z) mice 
PBN 100 25 O 0 0 
Compound l 100 I00 100 100 100 
Example 10 
Another undesirable systemic e?‘ect which has been 
observed in vivo with nitrone radical traps is a depression in 
body temperature. This toxicity can have serious health 
consequences and also can complicate diagnosis of other 
conditions. As detailed in FIGS. 2 and 4. the compound of 
this invention was administered to mice and gerbils at levels 
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as high as 1000 mg/kg with no measurable temperature 
decrease. In contrast. the compound of the art. PBN. gave up 
to an 8° C. decrease in body temperature at a does of only 
500 mg/kg. 
Example ll 
The compound of the invention was tested to determine 
its effectiveness in the treatment of conditions characterized 
by protracted low grade oxidative stress upon the central 
nervous system and gradual progressive central nervous 
system function loss by testing its e?ectiveness in a model 
for Alzheimer’s disease (“AD"). This model has the follow 
ing basis: Recent studies have demonstrated that there is an 
age-associated increase in protein oxidation and loss of 
enzyme activities in the brain of aged individuals. Tissue 
cultures of ?broblasts from aged individuals and red blood 
cells of different ages both show an exponential increase in 
protein carbonyl content (a measure of protein oxidation) 
and a decrease in marker enzyme activities. Brain protein 
oxidation progressively increases over the life span of the 
individual. 
The role of abnormal amyloid precursor peptide process 
ing and metabolism in AD has also been explored in a 
number of ditferent models. In vitro studies using embryonic 
hippocarnpal neuronal and neuronal/glia] cultures have dem 
onstrated that BAP l-40 produces cytotoxicity over an 
extended period of co-incubation. When this peptide is 
infused into rat brains. lesions are produced. Some of the 
proposed breakdown fragments of [SAP are also neurotoxic 
[c.g. PAP (25-35)|. The neurotoxicity appears to be both 
mediated via glutamate receptors. and also by non-glutamate 
receptors mechanisms. Confocal microscopy studies of neu 
ronal cultures have demonstrated that exposure to [SAP 
(1-40) results in oxidative stress [Dichloro?uorescein and 
increased intracellular free calcium Fura-Z}. 
It has been demonstrated that BAP fragments can directly 
inactivate glutamine synthetase (GS) and creatine kinase 
(CK) in tissue extracts and in cultured hippocampal neurons 
and glia (See A and B in FIG. 4). A and B of FIG. 4 present 
the dose-related inactivation of glutamine synthetase and 
creatine kinase by AP (25-35). (brtosolic fractions from 
gerbil neocortex were prepared and enzyme activities deter 
mined. Sarnples were incubated in the presence of different 
concentrations of the peptide for 10 min prior to assay. Solid 
symbols represent the effects of the naturally occurring 
25-35 fragment. Open circles indicate that the reverse 
sequence (32-25) had no effect on enzyme activity. Open 
triangles indicate that the scrambled amino acid sequence 
also had no effect on enzyme activities. compared to the 
effect of 25-35. Each point is the mean (+/— s.e.) of 5 
observations. BAP derived and other cellular sources of free 
radicals are an important determinant of the initiation and 
progression of AD. 
As demonstrated in C and D in FIG. 4. compound I and 
PBN each show the ability to protect GS and CK against the 
effects of BAP fragments. C and D of FIG. 4 present the 
protective effects of co-incubation of the cytosolic fractions 
with BAP 25-35 (0.4 mg/ml) in combination with djtferent 
concentrations of PBN (open circles) or compound I (closed 
circles). Each point is the mean (+/- s.e.) of 3 observations. 
As can be seen in C and D. compound I gives complete 
protection and in fact might even be able to reverse the 
effects of oxidation. In contrast. PBN‘s effectiveness is quite 
limited as it is asymptotically leveling out at a substantially 
incomplete level of protection. 
Example 12 
Experiments were carried out to further demonstrate the 
e?ectiveness of the compound of the invention in preventing 
central nervous system damage caused by stroke. 
5.780.5l0 
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Rat Focal Ischernia Results 
A pair of studies were done to determine the ef?cacy of 
Compound I in a rat focal ischemia model. In this model. 
Sprague Dawley rats (200-300 g) underwent a permanent 
middle cerebral artery occlusion (MCAO) to induce a focal 
stroke. Compound I was administered after the permanent 
occlusion as ?rst an intraperitoneal (i.p.) bolus dose and then 
by intravenous (i.v.) continuous infusion during the remain 
ing time up to 24 hours post stroke. The doses of Compound 
I used were either 100 mg/kg. i.p.. followed by 4.2 mg/kg/hr. 
i.v.. or 10 mg/kg. i.p.. followed by 0.42 mgkg/hr. iv. 
The rats were sacri?ced 3 days post stroke. the tissue was 
processed histologically using triphenyltetrazolium staining 
techniques. and the infarct volume. the area of total cell 
necrosis. was quantitated using image analysis. The results 
of these experiments are shown graphically in FIG. 5 and 
demonstrate that Compound I provided signi?cant 
protection. approximately 70%. in both studies. 
Comparison with Results in the Literature. 
Similar data have been reported recently for the com 
pound NOI‘ of this invention. PBN. by Cao and Phillis 
(Brain Research 664: 267-272. 1994). In their studies. rats 
underwent a permanent middle cerebral artery occlusion 
(MCAO) and a common carotid artery occlusion. The PBN 
was administered i.p. at 100 mg/kg at various times post 
stroke. The rats were sacri?ced 2 days post stroke and the 
infarct volume was quantitated using triphenyltetrazolium 
stain. 
When PBN was administered at 0.5. 5. 17. 29 and 41 
hours post stroke. or at 5. 17. 29. and 41 hours post stroke. 
the infarct volume was reduced in each case by approxi 
mately 50%. The cumulative dose of PBN administered to 
achieve 50% protection is at a minimum 4 times the amount 
of Compound I required for 70% protection. Thus. Com 
pound I is far superior to PBN in offering protection in the 
rat MCAO focal ischcrnia model. 
Example 13 
In this Example the compound of this invention 
(Compound I) was evaluated to determine its ability to 
ameliorate oxidation-caused side e?rects of anticancer 
therapy. 
Adriamycin Studies 
Adn'amycin is a widely used anticancer agent. It is known 
to be very effective but it is also known to have serious side 
effects arising from its tendency to cause oxidative damage. 
These side effects include causing serious levels of cardiac 
damage at high dose levels. These side effects have often 
limited the use of this agent or limited the dose levels that 
can be employed to levels which are below those desired for 
maximum antineoplastic disease effectiveness. 
Experiments were carried out to demonstrate that the 
compound of the invention is effective at reducing the side 
effects of anticancer agents such as adriamycin and permit 
ting higher dose levels of adriamycin to be tolerated by 
animals. 
C57B1J6J and DBA/2J male mice (35-40 g) were tested 
for the acute lethal elfects of adriamycin and the prevention 
of acute le?iality by pretreatment doses of Compound I. 
Mice were injected with either saline or Compound I 30 
minutes prior to administration of adriamycin. All injections 
were intraperitoneal. The acute lethality of adriamycin 
ranged from 10 to 30 mg/kg. The LDS0 for adriamycin in 
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these tests was found to be 25 mg/kg in both mouse strains. 
Compound I doses up to 300 mg/kg. without adriamycin 
treatment. had no effect on survival in the two mouse strains. 
Pretreatment with 30 and 100 mg/kg of Compound I 
produced dose related shifts in the adriamycin lethality dose 
effect curve. FIG. 6 shows the results obtained using the 
DEA/2] mouse. A dose of 100 mgkg of Compound I 
produced a 5-fold shift to the right (in the direction of 
reduced lethality). Thus. the combination of Compound I 
with adriamycin resulted in a marked increase in the maxi 
mally tolerated dose. These higher doses are in the range that 
would effectively kill multi-drug resistant tumors. 
Comparative Tests 
PBN pretreatment resulted in a slight shift to the right in 
the adriamycin does-e?’ect curve. While the Compound I 
dose could be increased to 300 mg/kg in combination with 
adriamycin. there was an upper limit for this combination 
with PBN. A dose of PBN of 100 mg/kg produced slight 
sedation and 300 mg/kg yielded marked sedation and some 
combined toxicity (IO-20% lethality). Compound 
Iladriamycin did not produce any combined toxicity at doses 
of Compound I of up to 300 mg/kg. 
Example 14 
Safety Testing. 
Compound I and PBN were tested for their acute toxicity 
in male Sprague Dawley (200-300 g) rats. The compounds 
were administered at 1000 mg/kg. i.p.. to groups of 6 rats. 
After 3 days lethality was assessed. Compound I caused no 
lethality. while PBN was lethal to 5 of the 6 rats used in this 
test. These data con?rm the gerbil data in that Compound I 
has higher safety than PBN. 
What is claimed is: 
1. A method for treating a patient who has suffered a 
concussion comprising administering to said patient an 
effective concussion treating amount of a pharmaceutical 
composition comprising the compound 2.4-disulfo alpha 
phenyl tertiary butyl nitrone in a pharmaceutically accept 
able carrier. 
2. The method of claim 1 wherein the composition is 
administered parenterally. 
3. The method of claim 2 wherein the composition is 
administered intraveneously. 
4. The method of claim 3 wherein the composition is 
administered in an amount of at least 0.2 mg/kg/hour. 
5. The method of claim 1 wherein the composition is 
administered orally. 
6. A method for treating a patient who has suffered a 
concussion comprising administering to said patient an 
e?’ective concussion treating amount of a pharmaceutical 
composition comprising a compound of the formula: 
in a pharmaceutically acceptable carrier. 
7. The method of claim 6 wherein the composition is 
administered parenterally. 
8. The method of claim 7 wherein the composition is 
administered intraveneously. 
9. The method of claim 8 wherein the composition is 
administered in an amount of at least 0.2 mgkg/hour. 
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10. The method of claim 6 wherein the composition is 
administered orally. 
11. A method for treating a patient who has sulfered a 
concussion comprising administering to said patient an 
e?ective concussion treating amount of a pharmaceutical 
composition comprising a pharmaceutically acceptable salt 
of: 
in a pharmaceutically acceptable carrier. 
12. The method of claim 11 wherein the composition is 
administered parenterally. 
13. The method of claim 12 wherein the composition is 
administered intraveneou sly. 
14. The method of claim 13 wherein the composition is 
administered in an amount of at least 0.2 mg/kg/hour. 
15. The method of claim 11 wherein the composition is 
administered orally. 
16. A method for treating a patient who has suffered a 
concussion comprising administering to said patient an 
effective concussion treating amount of a pharmaceutical 
composition comprising a compound of the formula: 
wherein X is selected from the group consisting of Na. K. 
N114. Ca. Mg. Zn. ZnY. CaY and MgY. wherein Y is a 
pharmaceutically acceptable monovalent anion. in a phar 
maceutically acceptable carrier. 
17. The method of claim 16 wherein the composition is 
administered parenterally. 
18. The method of claim 17 wherein the composition is 
administered intraveneously. 
19. The method of claim 18 wherein the composition is 
administered in an amount of at least 0.2 mg/kg/hour. 
20. The method of claim 16 wherein the composition is 
administered orally. 
21. A method for treating a patient who is suffering from 
a subarachnoid hemorrhage comprising administering to 
said patient an effective subarachnoid hemorrhage treating 
amount of a pharmaceutical composition comprising the 
compound 2.4-disulfo alpha-phenyl tertiary butyl nitrone in 
a pharmaceutically acceptable carrier. 
22. The method of claim 21 wherein the composition is 
administered parenterally. 
23. The method of claim 22 wherein the composition is 
administered intraveneously. 
24. The method of claim 23 wherein the composition is 
administered in an amount of at least 0.2 mg/kg/hour. 
25. The method of claim 21 wherein the composition is 
administered orally. 
26. A method for treating a patient who is su?ering from 
a subarachnoid hemorrhage comprising administering to 
said patient an effective subarachnoid hemorrhage treating 
amount of a pharmaceutical composition comprising a com 
pound of the formula: 
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in a pharmaceutically acceptable carrier. 
27. The method of claim 26 wherein the composition is 
administered parenterally. 
28. The method of claim 27 wherein the composition is 
administered intraveneously. 
29. The method of claim 28 wherein the composition is 
administered in an amount of at least 0.2 mg/kg/hour. 
30. The method of claim 26 wherein the composition is 
administered orally. 
31. A method for treating a patient who is sulfering from 
a subarachnoid hemorrhage comprising administering to 
said patient an e?‘ective subarachnoid hemorrhage treating 
amount of a pharmaceutical composition comprising a phar 
maceutically acceptable salt of: 
in a pharmaceutically acceptable carrier. 
32. The method of claim 31 wherein the composition is 
administered parenterally. 
33. The method of claim 32 wherein the composition is 
administered intraveneously. 
34. The method of claim 33 wherein the composition is 
administered in an amount of at least 0.2 mg/kg/hour. 
35. The method of claim 31 wherein the composition is 
administered orally. 
36. A method for treating a patient who is suifen'ng from 
a subarachnoid hemorrhage comprising administering to 
said patient an elfective subarachnoid hemorrhage treating 
amount of a pharmaceutical composition comprising a com 
pound of the formula: 
0 
wherein X is selected from the group consisting of Na. K. 
NR4. Ca. Mg. Zn. ZnY. CaY and MgY. wherein Y is a 
pharmaceutically acceptable monovalent anion. in a phar 
maceutically acceptable carrier. 
37. The method of claim 36 wherein the composition is 
administered parenterally. 
38. The method of claim 37 wherein the composition is 
administered intraveneou sly. 
39. The method of claim 38 wherein the composition is 
administered in an amount of at least 0.2 mg/kgfhour. 
40. The method of claim 36 wherein the composition is 
administered orally. 
